cCMP and cUMP: Emerging second messengers

Trends in Biochemical Sciences

Volumn 40, Issue 1, 2015, Pages 8-15

  Seifert, Roland ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bacterial toxins; cCMP; cUMP; Nucleotidyl cyclases; Phosphodiesterases; Protein kinases

Indexed keywords

ADENYLATE CYCLASE INHIBITOR; ADENYLATE CYCLASE TOXIN; BACTERIAL PROTEIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC CMP; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; CYCLIC UMP; DIBUTYRYLCYTIDINE 3',5' PHOSPHATE; EDEMA FACTOR; EXOPROTEIN Y; GUANYLATE CYCLASE INHIBITOR; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL; MULTIDRUG RESISTANCE PROTEIN; NUCLEOTIDYL CYCLASE TOXIN; ORGANIC ANION TRANSPORTER; PHOSPHODIESTERASE; PURINE; PYRIMIDINE; TOXIN; UNCLASSIFIED DRUG; ADENYLATE CYCLASE; BACTERIAL PROTEINS; BACTERIAL TOXINS; CYCLIC 3',5'-URIDINE MONOPHOSPHATE; EXOY PROTEIN, BACTERIA; GLUCOSYLTRANSFERASES; GUANYLATE CYCLASE; NUCLEOTIDES, CYCLIC; PHOSPHORIC DIESTER HYDROLASES; PROTEIN KINASES; URIDINE MONOPHOSPHATE;

ANTIBIOTIC RESISTANCE; BINDING SITE; CONCENTRATION (PARAMETERS); EPITHELIUM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; MEMBRANE PERMEABILITY; MESENCHYME CELL; NERVE CELL; NONHUMAN; NUCLEIC ACID ANALYSIS; NUCLEIC ACID METABOLISM; NUCLEIC ACID STRUCTURE; PATCH CLAMP TECHNIQUE; PRIORITY JOURNAL; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; RADIOMETRY; REVIEW; SECOND MESSENGER; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; TYPE III SECRETION SYSTEM; GENETICS; METABOLISM;

BACTERIA (MICROORGANISMS);

ADENYLATE CYCLASE; BACTERIAL PROTEINS; BACTERIAL TOXINS; CYCLIC CMP; GLUCOSYLTRANSFERASES; GUANYLATE CYCLASE; NUCLEOTIDES, CYCLIC; PHOSPHORIC DIESTER HYDROLASES; PROTEIN KINASES; PSEUDOMONAS AERUGINOSA; URIDINE MONOPHOSPHATE;

EID: 84925470905     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2014.10.008     Document Type: Review

References (52)

1. Hardman J.G., Sutherland E.W. A cyclic 3',5'-nucleotide phosphodiesterase from heart with specificity for uridine 3',5'-phosphate. J. Biol. Chem. 1965, 240:3704-3705.
2. Klotz U., Stock K. Evidence for a cyclic nucleotide-phosphodiesterase with high specificity for cyclic uridine-3',5'-monophosphate in rat adipose tissue. Naunyn Schmiedebergs Arch. Pharmacol. 1971, 269:117-120.
3. Cech S.Y., Ignarro L.J. Cytidine 3',5'-monophosphate (cyclic CMP) formation in mammalian tissues. Science 1977, 198:1063-1065.
4. Gaion R.M., Krishna G. Cytidylate cyclase: the product isolated by the method of Cech and Ignarro is not cytidine 3',5'-monophosphate. Biochim. Biophys. Res. Commun. 1979, 86:105-111.
5. Anderson T. Cyclic cytidine 3',5'-monophosphate (cCMP) in cell regulation. Mol. Cell. Endocrinol. 1982, 28:373-385.
6. Newton R.P., et al. Extraction, purification and identification of cytidine 3',5'-cyclic monophosphate from rat tissues. Biochem. J. 1984, 221:665-673.
7. Beghè B., et al. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am. J. Respir. Crit. Care Med. 2013, 188:271-278.
8. Redrow G.P., et al. Treatment strategies for diabetic patients suffering from erectile dysfunction: an update. Expert Opin. Pharmacother. 2014, 15:1827-1836.
9. Gille A., et al. Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J. Biol. Chem. 2004, 279:19955-19969.
10. Göttle M., et al. Molecular analysis of the interaction of Bordetella pertussis adenylyl cyclase with fluorescent nucleotides. Mol. Pharmacol. 2007, 72:526-535.
11. Göttle M., et al. Cytidylyl and uridylyl cyclase activity of Bacillus anthracis edema factor and Bordetella pertussis CyaA. Biochemistry 2010, 49:5494-5503.
12. Göttle M., et al. Bacillus anthracis edema factor substrate specificity: evidence for new modes of action. Toxins 2012, 4:505-535.
13. Vojtova J., et al. Bordetella adenylate cyclase toxin: a swift saboteur of host defense. Curr. Opin. Microbiol. 2006, 9:69-75.
14. 1. Biochemistry 2012, 51:194-204.
15. Beckert U., et al. The receptor-bound guanylyl cyclase DAF-11 is the mediator of hydrogen peroxide-induced cGMP increase in Caenorhabditis elegans. PLoS ONE 2013, 8:e72569.
16. Bähre H., et al. Nucleotidyl cyclase activity of soluble guanylyl cyclase in intact cells. Biochem. Biophys. Res. Commun. 2014, 443:1195-1199.
17. Hartwig C., et al. cAMP, cGMP, cCMP and cUMP concentrations across the tree of life: high cCMP and cUMP levels in astrocytes. Neurosci. Lett. 2014, 579:183-187.
18. Hasan A., et al. Soluble adenylyl cyclase accounts for the high basal cCMP and cUMP concentrations in HEK293 and B103 cells. Biochem. Biophys. Res. Commun. 2014, 448:236-240.
19. Sayner S.L., et al. Soluble adenylyl cyclase reveals the significance of cAMP compartmentation on pulmonary microvascular endothelial cell barrier. Circ. Res. 2006, 98:675-6781.
20. Steegborn C. Structure, mechanism, and regulation of soluble adenylyl cyclases - similarities and differences to transmembrane adenylyl cyclases. Biochim. Biophys. Acta 2014, Published online September 2, 2014. 10.1016/j.bbadis.2014.08.012.
21. Hammerschmidt A., et al. Binding of regulatory subunits of cyclic AMP-dependent protein kinase to cyclic CMP agarose. PLoS ONE 2012, 7:e39848.
22. Wolter S., et al. Differential activation of cAMP- and cGMP-dependent protein kinases by cyclic purine and pyrimidine nucleotides. Biochem. Biophys. Res. Commun. 2011, 415:563-566.
23. Monzel M., et al. PDE7A1 hdrolyzes cCMP. FEBS Lett. 2014, 588:3469-3474.
24. Beckert U., et al. cNMP-AMs mimic and dissect bacterial nucleotidyl cyclase toxin effects. Biochem. Biophys. Res. Commun. 2014, 451:497-502.
25. 4-monobutyryl-cCMP activates PKA RIα and PKA RIIα more potently and with higher efficacy than PKG Iα in vitro but not in vivo. Naunyn-Schmiedebergs Arch. Pharmacol. 2014, (in press).
26. Desch M., et al. Cyclic cytidine 3',5'-monophosphate (cCMP) signals via cGMP kinase I. FEBS Lett. 2010, 584:3979-3984.
27. Zong X., et al. Regulation of hyperpolarization-activated cyclic nucleotide-gated (HCN) channel activity by cCMP. J. Biol. Chem. 2012, 287:26506-26512.
28. Akimoto M., et al. A mechanism for the auto-inhibition of hyperpolarization-activated cyclic nucleotide-gated (HCN) channel opening and its relief by cAMP. J. Biol. Chem. 2014, 289:22205-22220.
29. Reinecke D., et al. Human cyclic nucleotide phosphodiesterases possess a much broader substrate-specificity than previously appreciated. FEBS Lett. 2011, 585:3259-3262.
30. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 2006, 58:488-520.
31. Laue S., et al. cCMP is a substrate for MRP5. Naunyn-Schimedebergs Arch. Pharmacol. 2014, 387:893-895.
32. Schwede F., et al. Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol. Ther. 2000, 87:199-226.
33. Schultz C., et al. Membrane-permeant derivatives of cyclic AMP optimized for high potency, prolonged activity, or rapid reversibility. Mol. Pharmacol. 1994, 46:702-708.
34. Beste K.Y., et al. Nucleotidyl cyclase activity of particulate guanylyl cyclase A: Comparison with particulate guanylyl cyclases E and F, soluble guanylyl cyclase and bacterial adenylyl cyclases CyaA and edema factor. PLoS ONE 2013, 8:e70223.
35. Beckert U., et al. ExoY from Pseudomonas aeruginosa is a nucleotidyl cyclase with preference for cGMP and cUMP formation. Biochem. Biophys. Res. Commun. 2014, 450:870-874.
36. Yahr T.L., et al. ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:13899-13904.
37. Ochoa C.D., et al. Pseudomonas aeruginosa exotoxin Y is a promiscuous cyclase that increases endothelial tau phosphorylation and permeability. J. Biol. Chem. 2012, 287:25407-25418.
38. Lee V.T., et al. Activities of Pseudomonas aeruginosa effectors secreted by the type III secretion system in vitro and during infection. Infect. Immun. 2005, 73:1695-1705.
39. Stevens T.C., et al. The Pseudomonas aeruginosa exoenzyme Y impairs endothelial cell proliferation and vascular repair following lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014, 306:L915-L924.
40. 4, 2'-O-dibutyryl cytidine 3':5'-cyclic monophosphate of neutrophil activation. Biochem. Biophys. Res. Commun. 1991, 174:258-267.
41. 2, 2'-O-dibutyryl guanosine 3':5'-cyclic monophosphate. Naunyn-Schmiedebergs Arch. Pharmacol. 1991, 343:370-376.
42. Chan P.J. The effect of cyclic cytidine 3',5'-monophosphate (cCMP) on the in vitro development, hatching and attachment of the mouse blastocyst. Experientia 1987, 43:929-930.
43. Chan P.J., et al. Regulation of mouse trophoblast giant cell nucleus development in hatched mouse blastocysts by cyclic cytidine 3',5'-monophosphate (cCMP). Experientia 1988, 44:774-775.
44. Morita Y., et al. Responses to Pseudomonas aeruginosa to antimicrobials. Front. Microbiol. 2014, 4:422.
45. Baldini R.L., et al. Assessing Pseudomonas virulence with the nonmammalian host model: Arabidopsis thaliana. Methods Mol. Biol. 2014, 1149:689-697.
46. Sofroniew M.V., Vinters H.V. Astrocytes: biology and pathology. Acta Neuropathol. 2010, 119:7-35.
47. Sprenger J.U., Nikolaev V.O. Biophysical techniques for detection of cAMP and cGMP in living cells. Int. J. Mol. Sci. 2013, 14:8025-8046.
48. Ziolo K.J., et al. Vibrio vulnificus biotype 3 multifunctional autoprocessing RTX toxin is an adenylate cyclase toxin essential for virulence in mice. Infect. Immun. 2014, 82:2148-2157.
49. Jackson E.K., Raghvendra D.K. The extracellular cyclic AMP-adenosine pathway in renal physiology. Annu. Rev. Physiol. 2004, 66:571-599.
50. Chassy B.M., et al. The acrasin activity of 3',5'-cyclic nucleotides. Proc. Natl. Acad. Sci. U.S.A. 1969, 64:296-303.
51. Civelli O., et al. G protein coupled receptor deorphanizations. Annu. Rev. Pharmacol. Toxicol. 2013, 53:127-146.
52. Rocheville M., et al. Mining the potential of label-free biosensors for seven-transmembrane receptor drug discovery. Prog. Mol. Biol. Transl. Sci. 2013, 115:123-142.